
Combinational Strategies to Overcome Resistance in Cancer Immunotherapy
🧠 Introduction
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering durable responses in some patients. Yet, resistance remains a major hurdle, limiting the full potential of these therapies. A new review highlights how combinational approaches can expand the benefits of ICIs and bring precision medicine closer to reality.
🔍 Research Summary
The study, published in Frontiers in Immunology, examines emerging strategies to counter tumor resistance to ICIs. Resistance arises from tumor-intrinsic factors, such as reduced immunogenicity, and tumor-extrinsic factors, including limited T cell infiltration. Combination therapies target these challenges through multiple mechanisms:
- Enhancing antigen processing and presentation
- Improving T cell infiltration and cytotoxicity
- Pairing ICIs with other immunotherapies or targeted agents
Clinical studies already show that combining ICIs with other treatments can improve patient survival and tumor control, extending the reach of immunotherapy to more cancer patients.
🌍 Broader Impact
This research underscores the importance of precision medicine in cancer immunotherapy. Identifying predictive biomarkers and tailoring treatment strategies could maximize patient response and minimize resistance. By advancing combination therapies, the field is moving closer to making the life-changing benefits of ICIs available to a wider population, aligning with APMAD’s mission to transform cancer care through innovation.
📎 Reference
@article{Alsaafeen2025, title = {Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors}, volume = {16}, ISSN = {1664-3224}, url = {http://dx.doi.org/10.3389/fimmu.2025.1546717}, DOI = {10.3389/fimmu.2025.1546717}, journal = {Frontiers in Immunology}, publisher = {Frontiers Media SA}, author = {Alsaafeen, Besan H. and Ali, Bassam R. and Elkord, Eyad}, year = {2025}, month = apr }
اترك تعليقاً